Effects of anti-tumor necrosis factor α agents on bone.
Effects of anti-tumor necrosis factor α agents on bone.
复制标题
DOI：
10.1097/bor.0b013e328356d212
复制
发表时间：
2012-09
影响因子：
5.1
通讯作者：
Griffin MR
中科院分区：
文献类型：
--
作者：
Kawai VK;Stein CM;Perrien DS;Griffin MR
在几种炎症性疾病中，肿瘤坏死因子抑制剂是有效的疾病控制药物。尽管抗肿瘤坏死因子药物在体外可以抑制骨丢失，但它们在预防骨质疏松症和骨折等临床相关结果中的作用尚未明确。有许多关于肿瘤坏死因子抑制剂对骨转换标志物影响的研究，但很少有测量骨密度或骨折的研究。大多数这些研究的样本量都很小，少数人有安慰剂对照组。总体而言，这些研究表明，抗肿瘤坏死因子治疗的抗吸收作用与控制疾病活动有关。肿瘤坏死因子抑制剂的抗吸收作用可能与其抗炎特性有关。到目前为止，研究还没有证明在预防骨丢失和骨折方面，肿瘤坏死因子抑制剂比传统的非生物疗法有任何优势。
TNF inhibitors are effective for achieving disease control in several inflammatory diseases. Although anti-TNF agents can inhibit bone loss in vitro, their role in the prevention of clinically relevant outcomes such as osteoporosis and fractures has not been clearly established. There are many studies of the effects of TNF inhibitors on markers of bone turnover; however few have measured bone mineral density (BMD) or fractures. Most of these studies have small sample sizes and a minority had a placebo control group. Overall these studies suggest that the anti-resorptive effects of anti-TNF therapy are related to control of disease activity. The antiresorptive effects of TNF inhibitors are likely related to their anti-inflammatory properties. Studies to date have not demonstrated any advantages of TNF inhibitors over traditional non biologic therapies in the prevention of bone loss and fractures.